ACER - Acer Therapeutics Inc Stock Price, Fair Value and News

0.66USD Market Closed

Market Summary

USD0.66

Market Closed

ACER Stock Price

View Fullscreen

ACER RSI Chart

ACER Valuation

Market Cap

16.1M

Price/Earnings (Trailing)

-0.33

Price/Sales (Trailing)

22.06

Price/Free Cashflow

-0.43

ACER Price/Sales (Trailing)

ACER Profitability

Return on Equity

-36.7%

Return on Assets

-346.28%

Free Cashflow Yield

-231.57%

ACER Fundamentals

ACER Revenue

Revenue (TTM)

731.8K

ACER Earnings

Earnings (TTM)

-48.5M

Breaking Down ACER Revenue

Last 7 days

-8.0%

Last 30 days

5.3%

Last 90 days

10.0%

Trailing 12 Months

-35.0%

How does ACER drawdown profile look like?

ACER Financial Health

Current Ratio

0.1

Debt/Equity

0.02

Debt/Cashflow

-11.68

ACER Investor Care

Shares Dilution (1Y)

49.41%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	731.8K	0
2021	3.1M	2.4M	1.6M	1.3M
2016	2.9M	2.9M	2.9M	2.9M
2015	1.3M	1.7M	2.1M	2.6M
2014	1.4M	1.4M	1.3M	1.3M
2013	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Acer Therapeutics Inc

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.

CEO	Mr. Christopher Schelling
WEBSITE	acertx.com
INDUSTRY	Biotechnology
EMPLOYEES	30

Acer Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Acer Therapeutics Inc? What does ACER stand for in stocks?

ACER is the stock ticker symbol of Acer Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acer Therapeutics Inc (ACER)?

As of Mon Nov 20 2023, market cap of Acer Therapeutics Inc is 16.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACER stock?

You can check ACER's fair value in chart for subscribers.

Is Acer Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ACER is over valued or under valued. Whether Acer Therapeutics Inc is cheap or expensive depends on the assumptions which impact Acer Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACER.

What is Acer Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Nov 20 2023, ACER's PE ratio (Price to Earnings) is -0.33 and Price to Sales (PS) ratio is 22.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACER PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Acer Therapeutics Inc's stock?

In the past 10 years, Acer Therapeutics Inc has provided -0.421 (multiply by 100 for percentage) rate of return.